Your browser doesn't support javascript.
loading
Design and campaign synthesis of pyridine-based histone deacetylase inhibitors.
Andrews, David M; Gibson, Keith M; Graham, Mark A; Matusiak, Zbigniew S; Roberts, Craig A; Stokes, Elaine S E; Brady, Madeleine C; Chresta, Christine M.
Affiliation
  • Andrews DM; Cancer and Infection Research, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. david.andrews@astrazeneca.com
Bioorg Med Chem Lett ; 18(8): 2525-9, 2008 Apr 15.
Article de En | MEDLINE | ID: mdl-18378451
ABSTRACT
A lead benzamide, bearing a cyanopyridyl moiety (3), was identified as a potent and low molecular weight histone deacetylase (HDAC) inhibitor. Various replacements of the cyano group were explored at the C3-position, along with the exploration of solubility-enhancing groups at the C5-position. It was determined that cyano substitution at the C3-position of the pyridyl core, along with a methylazetidinyl substituent at the C5-position yielded optimal HDAC1 inhibition and anti-proliferative activity in HCT-116 cells.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyridines / Conception de médicament / Antienzymes / Inhibiteurs de désacétylase d'histone Limites: Animals / Humans Langue: En Journal: Bioorg Med Chem Lett Sujet du journal: BIOQUIMICA / QUIMICA Année: 2008 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyridines / Conception de médicament / Antienzymes / Inhibiteurs de désacétylase d'histone Limites: Animals / Humans Langue: En Journal: Bioorg Med Chem Lett Sujet du journal: BIOQUIMICA / QUIMICA Année: 2008 Type de document: Article Pays d'affiliation: Royaume-Uni